ondansetron has been researched along with Dyskinesia, Drug-Induced in 7 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Dyskinesia, Drug-Induced: Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Twenty patients with schizophrenia who had neuroleptic-induced tardive dyskinesia were given 12 mg/day of ondansetron for 12 weeks in an open-label study." | 5.09 | Use of the selective serotonin 3 receptor antagonist ondansetron in the treatment of neuroleptic-induced tardive dyskinesia. ( Giladi, N; Korczyn, AD; Mosheva, T; Shabtay, H; Sirota, P, 2000) |
| "Prochlorperazine is a centrally acting dopamine receptor antagonist that is most commonly used for the treatment of nausea and vomiting." | 3.69 | Tardive dyskinesia as a result of long-term prochlorperazine use. ( Alberts, VA; Catalano, G; Poole, MA, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Kwan, C | 1 |
| Lévesque, C | 1 |
| Bédard, D | 1 |
| Frouni, I | 1 |
| Yesuf, JM | 1 |
| Hamadjida, A | 1 |
| Lévesque, D | 1 |
| Clarke, PB | 1 |
| Huot, P | 1 |
| Alberts, VA | 1 |
| Catalano, G | 1 |
| Poole, MA | 1 |
| Sirota, P | 2 |
| Mosheva, T | 2 |
| Shabtay, H | 1 |
| Giladi, N | 1 |
| Korczyn, AD | 2 |
| Zullino, DF | 1 |
| Eap, CB | 1 |
| Voirol, P | 1 |
| Shabtai, H | 1 |
| Naidu, PS | 1 |
| Kulkarni, SK | 1 |
| Simpson, GM | 1 |
| Kingsbury, SJ | 1 |
1 trial available for ondansetron and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
Use of the selective serotonin 3 receptor antagonist ondansetron in the treatment of neuroleptic-induced tardive dyskinesia.
Topics: Adult; Aged; Antipsychotic Agents; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; H | 2000 |
6 other studies available for ondansetron and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
Autoradiographic labelling of 5-HT
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Ondansetr | 2022 |
Tardive dyskinesia as a result of long-term prochlorperazine use.
Topics: Antiemetics; Dopamine Antagonists; Dyskinesia, Drug-Induced; Fatal Outcome; Female; Granisetron; Hum | 1996 |
Ondansetron for tardive dyskinesia.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Drug Interactions; Dyskinesia, Drug-Induced; Human | 2001 |
Treating tardive dyskinesia with ondansetron.
Topics: Aged; Dyskinesia, Drug-Induced; Female; Humans; Male; Middle Aged; Ondansetron; Schizophrenia; Serot | 2001 |
Reversal of neuroleptic-induced orofacial dyskinesia by 5-HT3 receptor antagonists.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug- | 2001 |
Possible duplicate publication.
Topics: Clinical Trials as Topic; Duplicate Publications as Topic; Dyskinesia, Drug-Induced; Follow-Up Studi | 2002 |